# Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy

> **NCT07189884** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital of Xiamen University** · enrollment: 33 (estimated)

## Conditions studied

- Locally Advanced Breast Cancer (LABC)

## Interventions

- **DRUG:** Pyrotinib Maleate Tablets + Dalpiciclib Isethionate Tablets + Standard Endocrine

## Key facts

- **NCT ID:** NCT07189884
- **Lead sponsor:** The First Affiliated Hospital of Xiamen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-23
- **Primary completion:** 2026-06-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07189884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07189884, "Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07189884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*